This suggests that the T cells induced by BRAF/MEK inhibition in melanoma tumors are not conducive to a heightened anti-PD-1 response and may not be tumor-specific but rather a non-specific immune response to cell death induced by the BRAF-targeted therapy. The gene discussed is BRAF; the disease is melanoma.